FDA
-
-
-
-
-
-
-
Purple Biotech Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
-
-
-
-
-
-
-
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
-
-
-
-
-
-
-
Purple Biotech Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
-
-
-
-
-
-
-
Purple Biotech Ltd. (PPBT) Acquires Immunorizon
-
-
-
-
-
-
-
Purple Biotech (PPBT) Appoints Lior Fhima as Chief Financial Officer
-
322,299 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

